Ovarian Cancer

Also in TTHealthWatch: CVD death and obesity

"How are we here in 2023 having some of these discussions?" bemoans gynecologic cancer expert

Experts will discuss the chemotherapy drug shortages and the impact on patients

"Practice changing" findings for tough-to-treat patient population

Questions about anti-PD-L1 contribution, cost, and access to durvalumab, bevacizumab, olaparib

Moreover, a significant proportion do not qualify for genetic screening under current guidelines

It's less clear-cut for postmenopausal women, study authors say

Prospective study in heavily treated population is warranted, researcher says

High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib

Responses in a fourth of patients, clinical benefit in up to 90%

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

Significant PFS results demonstrated in NORA trial don't extend to overall survival

Mirvetuximab soravtansine produced responses in almost a third of patients in pivotal trial